Mr. Rene Goehrum reports

BIOSYENT RELEASES RESULTS FOR THIRD QUARTER AND FIRST NINE MONTHS OF 2015

BioSyent Inc. released today a summary of its financial results for the three and nine months ending Sept. 30, 2015. Key highlights include:

• Third-quarter 2015 revenues of $4,646,236 increased by 28 per cent against third-quarter 2014.
• First-nine-month 2015 revenues of $11,546,334 increased by 26 per cent against year-to-date 2014.
• Year-to-date 2015 pharmaceutical revenues of $10,633,525 increased by 28 per cent against year-to-date 2014.
• Year-to-date 2015 net revenues have grown at a compound annual growth rate (CAGR) of 43 per cent over the corresponding previous two years.
• Third-quarter 2015 earnings before interest, taxes, depreciation and amortization (1) of $1,619,701 increased by 20 per cent over third-quarter 2014.
• Year-to-date 2015 EBITDA of $4,110,130 increased by 27 per cent over year-to-date 2014.
• Third-quarter 2015 net income after tax of $1,188,536 increased by 19 per cent against third-quarter 2014.
• Year-to-date 2015 net income after tax of $3,002,287 increased by 25 per cent over year-to-date 2014.
• Third-quarter 2015 fully diluted earnings per share were eight cents as compared with seven cents in the prior-year period.
• Year-to-date 2015 fully diluted EPS of 21 cents grew by 24 per cent over year-to-date 2014.
• Trailing 12-month fully diluted EPS (2) of 26 cents was 24 per cent higher than 21 cents in the corresponding prior-year period.
• Return on equity was 40 per cent for the preceding 12 months ending Sept. 30, 2015.
• In Canada, the FeraMAX150 share of the oral iron market (doses) increased by 19 per cent in the January to August, 2015, period against the corresponding 2014 period (source data: IMS Health).
• The company remains debt free and has an unutilized operating line of credit with Royal Bank of Canada of $1.55-million.
• Working capital, which is the difference between current assets and current liabilities, increased by 28 per cent from $7,786,460 as at Dec. 31, 2014, to $9,955,794 as at Sept. 30, 2015.
• Total shareholders' equity increased by 39 per cent from $8,160,092 at Dec. 31, 2014, to $11,329,548 at Sept. 30, 2015.

"During the third quarter of 2015, while the company's existing products continued to grow, the company also signed an exlusive licence agreement to sell the Cysview product in Canada," commented Rene Goehrum, president and chief executive officer of BioSyent. "Cysview is an innovative technology that aids in the diagnosis and management of non-muscle-invasive bladder cancer. Cysview is synergistic with our existing product portfolio and represents a significant investment in our hospital business unit. The marketing authorization for Cysview was recently successfully transferred to BioSyent Pharma from our partner, Photocure ASA. The company is now in final preparations for the launch of Cysview to the Canadian market."

The chief executive officer presentation on the third-quarter 2015 results is available at the company's website.

The company's interim unaudited condensed consolidated financial statements and management's discussion and analysis will be posted on SEDAR on Nov. 11, 2015.

                                                            

   INTERIM UNAUDITED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME      
                                                            
                     Q3 2015       Q3 2014      YTD 2015      YTD 2014
Net
revenues           4,646,236     3,632,128    11,546,334     9,152,624
EBITDA             1,619,701     1,346,008     4,110,130     3,243,387
EBITDA % to
revenues                 35%           37%           36%           35%
Cost of
goods sold         1,084,943       841,994     2,532,723     2,015,272
Gross
profit             3,561,293     2,790,134     9,013,611     7,137,352
Total
operating
expense            1,939,373     1,439,489     4,897,336     3,879,180
Net income
Before tax         1,621,920     1,350,645     4,116,275     3,258,172
Tax
(including
deferred
tax)                 433,384       349,991     1,113,988       857,292
Net income
after tax          1,188,536     1,000,654     3,002,287     2,400,880
Net income
after tax %
to revenues              26%           28%           26%           26%

(1) EBITDA is a non-IFRS (international financial reporting standards)
financial measure. The term EBITDA does not have
any standardized meaning under international financial reporting
standards and therefore may not be comparable with similar
measures presented by other companies. The company defines EBITDA as
earnings before interest income or expense, income taxes, and
depreciation and amortization.
(2) Trailing 12-month fully diluted earnings per share 
is a non-IFRS financial measure. The term TTM fully diluted EPS does
not have any standardized meaning under IFRS and therefore may not be
comparable with similar measures presented by other companies. The
company defines TTM fully diluted EPS as the sum of the fully diluted
EPS of the four most recently completed financial quarters.

We seek Safe Harbor.